

Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) - Drug Insight and Market Forecast - 2030

<https://marketpublishers.com/r/V8B2B736B164EN.html>

Date: February 2020

Pages: 50

Price: US\$ 2,750.00 (Single User License)

ID: V8B2B736B164EN

Abstracts

This report can be delivered to the clients within 48 Hours

OVERVIEW

“Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) - Drug Insight and Market Forecast – 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

SCOPE OF THE REPORT

The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

Elaborated details on regulatory milestones and other development activities have been provided in this report.

The report also highlights the drug marketed details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonico α , a recombinant human von Willebrand factor (rVWF)] (EU).

The report contains historical and forecasted sales for Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonico α , a recombinant human von Willebrand factor (rVWF)] (EU) till 2030.

Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

The report also features the SWOT analysis with analyst insights and key findings of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonico α , a recombinant human von Willebrand factor (rVWF)] (EU).

METHODOLOGY

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonico α , a recombinant human von Willebrand factor (rVWF)] (EU) Analytical Perspective by

Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonico α , a recombinant human von Willebrand...

DelveInsight

In-depth Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) Market Assessment

This report provides a detailed market assessment of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) Clinical Assessment

The report provides the clinical trials information of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) covering trial interventions, trial conditions, trial status, start and completion dates.

REPORT HIGHLIGHTS

In the coming years, the market scenario for Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Other approved products for the disease are giving market competition to Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a

recombinant human von Willebrand factor (rVWF)] (EU) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU).

Our in-depth analysis of the sales data of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) in the market.

KEY QUESTIONS

What is the prescribed dosage and strengths of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) are available in the market?

What are the common adverse reactions or side effects of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

What is the product type, route of administration and mechanism of action of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

What are the chemical specifications of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

How are the clinical trials diversified on the basis of the trial status?

What is the history of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor

(rVWF)] (EU), and what is its future?

What are the marketed details of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

How many patents have been granted to Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) and when these patents will get expire?

What are the pros (benefits) and cons (disadvantages) of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

In which countries Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) got approval and when it gets launched?

What are the clinical trials are currently ongoing for Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

How the safety and efficacy results determined the approval of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) development?

What are the key designations that have been granted to Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

What is the historical and forecasted market scenario of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

How is the market trend of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?

What are the other approved products available and how these are giving competition to Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)?

Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Contents

1. PRODUCT OVERVIEW

- 1.1. Indication
- 1.2. Mechanism of Action
- 1.3. Dosage and Administration
 - 1.4.1 Dosage Forms and Strengths
- 1.4. Route of Synthesis
- 1.5. Pharmacology
 - 1.4.2 Pharmacodynamics
 - 1.4.3 Pharmacokinetics
- 1.6. Adverse Reactions
- 1.7. Product Snapshot
- 1.8. Development Milestones of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)
- 1.9. Marketed Details
 - 1.4.4 United States
 - 1.4.5 Europe
 - 1.4.6 Japan
- 1.10. Patent Details

2. SWOT ANALYSIS

- 2.1. Analyst Views

3. REGULATORY MILESTONES

- 3.1. Approvals
- 3.2. Research and Development
- 3.3. Clinical Trials Information
- 3.4. Safety and Efficacy
- 3.5. Product Developmental Activities

4. MARKET ASSESSMENT

- 4.1. 7MM Market Analysis
- 4.2. United States

4.3. Europe

4.4. Japan

4.5. Key Findings

5. MARKET COMPETITORS

6. EMERGING THERAPIES

7. APPENDIX

7.1. Report Purchase Options

List Of Tables

LIST OF TABLES

Table 1 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Description

Table 2 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Trial Diversification

Table 3 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Marketed Details United States

Table 4 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Marketed Details Europe

Table 5 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Marketed Details Japan

Table 6 Patent Details: Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)

Table 7 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Clinical Trial Description, 2020

Table 8 Safety and Efficacy Results for Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)

Table 9 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), 7MM Market Size from 2017 to 2030 (in Million USD)

Table 10 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), US Market Size from 2017 to 2030 (in Million USD)

Table 11 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), EU Market Size from 2017 to 2030 (in Million USD)

Table 12 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), EU5 Market Size from 2017 to 2030 (in Millions USD)

Table 13 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Japan Market Size from 2017 to 2030 (in Million USD)

Table 14 Market Competitors

Table 15 Emerging Therapies

List Of Figures

LIST OF FIGURES

Figure 1 The Development Timeline of Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)

Figure 2 Patent Details, Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU)

Figure 3 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), 7MM Market Size from 2017 to 2030 (in Million USD)

Figure 4 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), US Market Size from 2017 to 2030 (in Millions USD)

Figure 5 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), EU Market Size from 2017 to 2030 (in Millions USD)

Figure 6 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), EU5 Market Size from 2017 to 2030 (in Millions USD)

Figure 7 Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicog alfa, a recombinant human von Willebrand factor (rVWF)] (EU), Japan Market Size from 2017 to 2030 (in Millions USD)

I would like to order

Product name: Vonvendi [von Willebrand factor (recombinant)] (US)/VEYVONDI [vonicoq alfa, a recombinant human von Willebrand factor (rVWF)] (EU) - Drug Insight and Market Forecast - 2030

Product link: <https://marketpublishers.com/r/V8B2B736B164EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V8B2B736B164EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970